Skip to main content
HYPR
NASDAQ Industrial Applications And Services

Hyperfine Q2 Revenue Jumps 45% to $3.9M, Losses Narrow; Cash Runway Extended Through 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.96
Mkt Cap
$97.483M
52W Low
$0.85
52W High
$2.22
52W Position info
13% above low
Off High info
57% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

HYPR is trading near its 52-week low of $0.85 (13% above the low) on light trading volume (0.4× avg).

Summary

Hyperfine reported Q2 2026 revenue of $3.9 million, up 45% year-over-year, with a narrowed net loss of $9.3 million. Cash of $43.5 million and management's statement that existing resources fund operations for at least 12 months remove the prior going concern doubt.


Key Events · Earnings and Guidance · HYPR

  • Revenue Growth Accelerates

    Driven by higher device unit sales and a higher average selling price, Q2 2026 revenue reached $3.9 million, a 44.8% increase from $2.7 million in Q2 2025. First-half revenue of $7.8 million was up 61.5% year-over-year.

  • Losses Narrow, Cash Burn Improves

    The net loss was $9.3 million in Q2 2026, essentially flat versus $9.2 million a year ago, while operating cash burn improved to $16.3 million in H1 2026 from $17.2 million in H1 2025.

  • Going Concern Risk Removed

    Management states that existing cash and equivalents of $43.5 million, together with anticipated revenue, are sufficient to fund operations for at least 12 months from the filing date. This removes the substantial doubt about the company's ability to continue as a going concern that had been present in prior filings.

  • ATM Program Raises $11.4M in H1 2026

    Under its at-the-market program, the company sold 7.8 million shares in H1 2026, generating net proceeds of $11.4 million. In Q2 alone, 7.1 million shares were sold for net proceeds of $10.6 million, contributing to the strengthened cash position but also diluting existing shareholders.


Analysis · HYPR · Industrial Applications And Services

A 45% surge in quarterly revenue to $3.9 million—driven by higher device sales and better pricing—marks Hyperfine's strongest quarter yet. The net loss narrowed slightly, and with $43.5 million in cash, management now says it has enough to fund operations for at least 12 months, effectively removing the going concern risk that had weighed on the stock. Aggressive ATM sales raised $11.4 million in the first half, and a new $15 million term loan further bolstered the balance sheet. While the ATM adds dilution, accelerating revenue, improving margins, and a secure cash runway signal a turning point for this commercial-stage medtech.

At the time of this filing, HYPR was trading at $0.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $97.5M. The 52-week trading range was $0.85 to $2.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HYPR - Latest Insights

HYPR
May 12, 2026, 4:40 PM EDT
Filing Type: S-3
Importance Score:
7
HYPR
May 12, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
8
HYPR
May 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
HYPR
Apr 08, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
HYPR
Mar 18, 2026, 4:21 PM EDT
Filing Type: 10-K
Importance Score:
8